Home
Biogen and UCB Results: Phase 3 PHOENYCS GO Study Evaluating Dapirolizumab Pegol Demonstrated a Reduction in Systemic Lupus Erythematosus Disease Activity

Biogen and UCB Results: Phase 3 PHOENYCS GO Study Evaluating Dapirolizumab Pegol Demonstrated a Reduction in Systemic Lupus Erythematosus Disease Activity

Today’s Highlights November 19, 2024

Biogen & UCB Announcement

Today, November 19, 2024, UCB (Euronext Brussels: (UCB) and Biogen (BIIB) presented . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Today’s Highlights
,
November 19, 2024

Other Articles